These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1736 related items for PubMed ID: 17549293

  • 1. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 2. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ, Bukuya M, Martinelli T, Tzouroutis J, Duncan E, Welldon K, Collecutt M, Aumann H, Thom J, Gilmore G.
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [Abstract] [Full Text] [Related]

  • 3. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ, Kershaw G, McLachlan AJ, Lloyd J.
    Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
    [Abstract] [Full Text] [Related]

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 5. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 8. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Jul 01; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep 01; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S, Carlson M, Hillarp A.
    Haemophilia; 2004 May 01; 10(3):243-9. PubMed ID: 15086321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J, Dunkley S, Rickard K, Baker R, Street A.
    Haemophilia; 2007 Mar 01; 13(2):144-8. PubMed ID: 17286766
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL, Siekmann J, Schwarz HP.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):149-60. PubMed ID: 11992238
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):203-14. PubMed ID: 11992243
    [Abstract] [Full Text] [Related]

  • 20. Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.
    Raquet E, Stockschläder M, Dickneite G.
    Haemophilia; 2011 Sep 01; 17(5):808-14. PubMed ID: 21726357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 87.